EICHORPublic-registry site landscape for NCT01591902, “Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®”, a Diabetic Retinopathy study sponsored by Theratechnologies. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01591902 (registry record) |
| Study title | Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA® |
| Official title | A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes |
| Sponsor | Theratechnologies |
| Condition(s) | Diabetic Retinopathy; HIV |
| Phase | PHASE4 |
| Listed sites | 24 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT01591902.
Eichor generates a preliminary site-risk snapshot for NCT01591902 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Diabetic Retinopathy trials
← Eichor home · All tracked trials · Diabetic Retinopathy studies · Weekly briefs
